Larry Goldstein to Cholesterol
This is a "connection" page, showing publications Larry Goldstein has written about Cholesterol.
Connection Strength
0.941
-
Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2009 Nov; 40(11):3526-31.
Score: 0.304
-
Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke. 2008 Sep; 39(9):2444-8.
Score: 0.281
-
Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011 Oct; 68(10):1245-51.
Score: 0.086
-
Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2010 Mar; 41(3):426-30.
Score: 0.078
-
Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke. 2009 Jul; 40(7):2486-92.
Score: 0.074
-
10 questions about statins and stroke. Neurologist. 2008 Jul; 14(4):262-4.
Score: 0.070
-
Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study. Cerebrovasc Dis. 2003; 16(4):389-95.
Score: 0.048